<DOC>
	<DOCNO>NCT01982682</DOCNO>
	<brief_summary>This phase II trial study well total-body irradiation , donor lymphocyte infusion , cyclophosphamide donor stem cell transplant work treat patient high-risk hematologic malignancy . Giving total-body irradiation , donor lymphocyte infusion , chemotherapy donor stem cell transplant help stop growth cancer abnormal cell help stop patient 's immune system reject donor 's stem cell . When certain stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Removing T cell donor cell transplant give tacrolimus mycophenolate mofetil may stop happening .</brief_summary>
	<brief_title>Allogeneic Hematopoietic Stem Cell Transplantation High-Risk Hematologic Malignancies Using One Haploidentical Donor</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : 1 ) To assess 1 year relapse free survival high risk patient undergoing hematopoietic stem cell transplant ( HSCT ) use Thomas Jefferson University ( TJU ) 2 step approach 2 day insert last fraction total-body irradiation ( TBI ) infusion donor T cell ( donor lymphocyte infusion [ DLI ] ) . SECONDARY OBJECTIVES : 1 . To assess regimen related toxicity update condition regimen , graft-versus-host disease ( GVHD ) incidence severity , overall survival patient undergoing treatment protocol . 2 . To assess consistency pace engraftment . 3 . To assess pace T cell B cell immune recovery . OUTLINE : CONDITIONING REGIMEN : Patients undergo TBI twice daily ( BID ) day -10 -8 , undergo DLI day -6 , receive cyclophosphamide intravenously ( IV ) 2 hour day -3 -2 . TRANSPLANT : Patients undergo cluster differentiation ( CD ) 34+ select allogeneic HSCT day 0 . GVHD PROPHYLAXIS : Patients receive tacrolimus IV orally ( PO ) begin day -1 taper begin day 42 , mycophenolate mofetil IV BID day -1 28 . After completion study treatment , patient follow 1 year .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1 . This treatment patient high risk hematologic malignancy . High risk define : Any patient hematologic malignancy residual disease treatment 1 chemotherapy regimen achievement remission additional chemoradiotherapy felt unlikely Patients without morphologic evidence disease high risk feature would predict relapse despite remission HSCT adverse cytogenetics , 3rd great CR , failure recover peripheral blood count normal range . While patient detectable disease current method , like patient nondetectable disease case highly aggressive . 2 . Patients must one relate donor HLA mismatch GVHD direction two HLA loci 3 . Patients must adequate organ function : LVEF &gt; 50 % DLCO ( adjust hemoglobin ) &gt; 50 % predict FEV1 &gt; 50 % Adequate liver function define serum bilirubin &lt; 1.8 , AST ALT &lt; 2.5X upper limit normal Creatinine clearance &gt; 60 ml/min 4 . Karnofsky Performance Status &gt; 80 % modify KPS tool 5 . Patients must willing use contraception childbearing potential 6 . Able give inform consent 1 . Modified KPS &lt; 80 % 2 . &gt; 5 Comorbidity Points HCTCI Index ( See Appendix B ) 3 . Class I II antibody donor HLA antigens 4 . HIV positive 5 . Active involvement central nervous system malignancy 6 . Psychiatric disorder would preclude patient sign informed consent 7 . Pregnancy , unwillingness use contraception child bear potential 8 . Patients life expectancy &lt; 6 month reason underlie hematologic/oncologic disorder 9 . Alemtuzumab treatment within 8 week HSCT admission 10 . ATG level &gt; 2 ugm/ml 11 . Patients active inflammatory process include T max &gt; 101 active tissue inflammation exclude 12 . Inability tolerate cyclophosphamide undergo total body irradiation dose specify treatment plan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>